Pharmaceutical segment
Offset 9.2 billion yen in incomes losses due to NHI price revisions to continue growth.
Domestic ethical pharmaceuticals
Maintaining strong presence with No. 2 share for both systemic antibacterial drugs and antidepressant drugs
Release new drugs in areas of strength for both brand-name and generic markets.
-Sycrest, antipsychotic drug, is scheduled for release in May.
-Anti-allergy drug, COPD drugs
-Enhance generic lineup
Promote those new drugs together with existing products and maximize the first year sales.
Agrochemical and veterinary drugs
Accelerate selection and concentration and improve profitability – break-even
Continue structural reforms to establish a stable profit structure
Offset 9.2 billion yen in incomes losses due to NHI price revisions to continue growth.
Domestic ethical pharmaceuticals
Maintaining strong presence with No. 2 share for both systemic antibacterial drugs and antidepressant drugs
Release new drugs in areas of strength for both brand-name and generic markets.
-Sycrest, antipsychotic drug, is scheduled for release in May.
-Anti-allergy drug, COPD drugs
-Enhance generic lineup
Promote those new drugs together with existing products and maximize the first year sales.
Agrochemical and veterinary drugs
Accelerate selection and concentration and improve profitability – break-even
Continue structural reforms to establish a stable profit structure